Small-cell lung cancer (SCLC) is an exceptionally aggressive disease with poor prognosis. Here, we obtained exome, transcriptome and copy-number alteration data from approximately 53 samples consisting of 36 primary human SCLC and normal tissue pairs and 17 matched SCLC and lymphoblastoid cell lines. We also obtained data for 4 primary tumors and 23 SCLC cell lines. We identified 22 significantly mutated genes in SCLC, including genes encoding kinases, G protein-coupled receptors and chromatin-modifying proteins. We found that several members of the SOX family of genes were mutated in SCLC. We also found SOX2 amplification in ~27% of the samples. Suppression of SOX2 using shRNAs blocked proliferation of SOX2-amplified SCLC lines. RNA sequencing identified multiple fusion transcripts and a recurrent RLF-MYCL1 fusion. Silencing of MYCL1 in SCLC cell lines that had the RLF-MYCL1 fusion decreased cell proliferation. These data provide an in-depth view of the spectrum of genomic alterations in SCLC and identify several potential targets for therapeutic intervention.
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VOLUME 44 | NUMBER 10 | OCTOBER 2012 Nature GeNetics l e t t e r s Table 3 ). We validated all of the indels reported using Sanger sequencing (Supplementary Table 4) . One sample represented a distinct profile, with 2,953 mutations (757 validated proteinaltering variants; Fig. 1a and Supplementary Table 3) . Given the exceptionally high number of mutations in this sample, we excluded it from our calculations of the background mutation rate. Excluding the hypermutated sample, the SCLC tumors had an average of 175 protein-altering single-nucleotide variants (range 31-388) with a mean nonsynonymous mutation rate of 5.5 mutations per megabase (Fig. 1a) . This is comparable to the 92 protein-altering variants observed in the previously sequenced genome of a single SCLC cell line 13 . Analysis of the base-level transitions and transversions showed that G-to-T transversions were predominant, followed in prevalence by G-to-A and A-to-G transitions (Fig. 1b) , both at the exome (Fig. 1c) and wholegenome (Fig. 1d,e and Supplementary Fig. 1 ) levels. This pattern is consistent with demonstrated effects of tobacco smoke carcinogens on DNA 13 .
RNA-seq data (Supplementary
In assessing the whole-genome data for an SCLC tumor-normal tissue pair, we found 59,784 somatic mutations, of which 286 were protein-altering changes (256 missense, 19 nonsense, 11 essential splice site, 77 synonymous, 13,924 intronic and 45,497 others). The average whole-genome mutation rate was 21.34 mutations per megabase (Fig. 1d) . Previously, 22,910 somatic variants were reported for the NCI-H209 SCLC cell line 13 .
Our mutation analysis identified protein-altering somatic singlenucleotide variants in 5,179 genes, including 4,775 genes that were mutated in the non-hypermutated SCLC sample set. Frequently mutated classes included genes encoding kinases, G protein-coupled receptors and chromatin-modifying proteins. To further understand the impact of the mutations on gene function, we applied SIFT 14 , Polyphen 15 and Condel 16 and found that ~53% of the somatic mutations identified are likely to have functional consequences according to at least two of the three methods (Supplementary Table 3 ). In contrast, only approximately 17% of germline variants identified in the normal samples are predicted by these methods to have a functional impact (Supplementary Fig. 2) .
To further assess the relevance of mutated genes, we applied a q-score metric 17 to rank significantly mutated cancer-associated genes. We identified 22 significantly mutated genes in SCLC (q score ≥ 1; false discovery rate ≤ 10%; Supplementary Table 5) . These genes included TP53 and RB1 and several genes that have not previously been reported as mutated in SCLC ( Fig. 2a and Supplementary Table 5 ). npg l e t t e r s
To further confirm the relevance of the 22 genes, we assessed the mutation frequency for these genes using exome data from a set of 21 additional samples (Supplementary Table 6 ). We found a significant correlation between the mutation frequencies of the 22 genes in the initial sample set and the validation cohort (P = 1.16 × 10 −5 , r 2 = 0.63; Supplementary Table 7 ). In addition, we found that 42 genes that were mutated in our primary tumor samples (Supplementary Table 8) were also previously reported to be mutated in the genome of the NCI-H209 SCLC cell line 13 . Mutational hotspots are indicative of genes that are relevant to cancer. In this study, we have identified 17 genes with 18 hotspot mutations (Supplementary Table 9 ). By comparing our mutations with those reported in COSMIC 12 and a large-scale colon cancer mutation screen 18 , we identified an additional 150 hotspot mutations in 116 genes (Supplementary Fig. 2b ) and DNA repair and/or checkpoint pathway genes (ATM, ATR, CHEK1 and CHEK2). The mutations in SOX family members were mutually exclusive ( Supplementary Fig. 3 ). In contrast to non-small-cell lung cancer (NSCLC) 12 , we did not observe any SCLC samples with a KRAS mutation. Among the receptor tyrosine kinase genes, we identified mutations in FLT1, FLT4, KDR and KIT and members of the Ephrin family (EPHA1-7 and EPHB4). Notably, VOLUME 44 | NUMBER 10 | OCTOBER 2012 Nature GeNetics l e t t e r s the KIT mutation affecting codon 761 has previously been reported in mast cell activation disorder and is likely an activating change 19 ( Supplementary Fig. 4) .
Chromosomal copy-number analysis of 56 SCLC samples identified recurrent copy gains and losses (Supplementary Tables 11 and 12) . Genes with copy-number loss included the previously reported RB1, RASSF1 and FHIT (Fig. 3) and several genes not previously known to be altered in SCLC, including KIF2A and CNTN3 (refs. 6,20) . Among the genes with recurrent copy-number gain, we confirmed previously reported amplifications involving MYC, SOX4 and KIT (Fig. 3a,  Supplementary Fig. 4b and Supplementary Table 11 ) 6, 20, 21 .
In addition, we identified high levels of amplification (copy number of ≥4) of SOX2 in ~27% (15/56) of the SCLC samples (Fig. 3b) . RNAseq data showed that the majority of the SCLC samples, including those with SOX2 amplification, had higher SOX2 expression compared to adjacent normal samples (Fig. 3c) . We further examined the expression of SOX2 by immunohistochemistry (IHC) and copy-number change by FISH in an independent cohort of 110 primary SCLC tumor samples (Fig. 4a,b) . Expression of SOX2 was strongly correlated with increased gene copy number and with clinical stage (Fig. 4c,d) .
To further assess the relevance of SOX2 in SCLC, we analyzed a panel of SCLC cell lines for SOX2 protein expression and gene copy number (Supplementary Fig. 5 ). Among these cell lines, H446 and H720 both had strong SOX2 protein expression, and H720 was found to have elevated gene copy number. SOX2 has previously been implicated in the maintenance of proliferative potential and stem cell function [22] [23] [24] [25] . To test whether H446 and H720 were dependent on SOX2 for continued growth and proliferation, we stably transduced them with lentiviruses carrying either a doxycycline-inducible SOX2-targeting short hairpin RNA (shRNA) or a scrambled control shRNA.
Induction of SOX2 shRNA in both H446 and H720 resulted in lower amounts of SOX2 protein and reduced cell proliferation (Fig. 3d,e) . Previously, amplification of SOX2 and its role as an oncogene have been reported in lung and esophageal squamous cell carcinoma 26 . Our findings further support the idea of SOX2 as a genuine SCLC driver gene. Analysis of RNA-seq data obtained from SCLC samples for fusion transcripts Fig. 6a ) was found in one primary SCLC tumor and four SCLC cell lines (H889, HCC33, H1092 and COR-L47). RLF and MYCL1 are ~259 kb apart and are encoded by opposing strands. The observed fusion requires an inversion event that brings exon 1 of RLF in frame with MYCL1, leading to the expression of a fusion protein composed of the first 79 amino acids of RLF and a MYCL1 protein lacking its first 27 amino acids, thereby generating a 446-residue fusion protein. The clinical sample that had the RLF-MYCL1 fusion also overexpressed MYCL1. This fusion has previously been noted 27 , but its role as an oncogene in SCLC has not been established. We found that small interfering RNA (siRNA)-mediated targeting of MYCL1 in H1092 and CORL47 fusion-positive cells effectively reduced the proliferation of these cells, strongly suggesting a functional role for MYCL1 in SCLC (Supplementary Fig. 6 ). Multiple gene fusions involving kinase genes have recently been shown to be activating 28 . We identified four such fusions-NPEPPS-EPHA6, SKP1-CDKL3, NEK4-SFMBT1 and ZAK-RAPGEF4-that are predicted by sequence to result in functional fusion proteins ( Fig. 5 and Supplementary Figs. 7-9 ). The roles of these fusion products in cancer remain to be elucidated.
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In this study, we have identified multiple new recurrent somatic mutations in SCLC, including multiple mutations and copy-number alterations in SOX gene family members. The potential role of SOX family members in SCLC is further emphasized here by the identification of SOX2 amplification and overexpression in approximately a quarter of the SCLC samples analyzed. SOX proteins have an important role in diverse biological processes, including cell type specification. Among the SOX family members, SOX2 in particular is a key factor in the maintenance of pluripotency and self-renewal of stem cells 23 . Aberrant SOX2 expression has also been implicated in reprogramming mature cells to acquired pluripotency 24 . Its expression in mouse fibroblasts, together with FoxG1, has been shown to generate self-renewing neural precursor cells 25 . Conditional deletion of Sox2 in mice indicates its critical role in lung development 22 . Conversely, overexpression of SOX2 in lung epithelial cells has been shown to promote tumorigenesis 29 .
Notably, conditional induction of SOX2 in lung epithelial cells is also known to increase the number of neural progenitor cells 30 . SCLCs are tumors with neuroendocrine features. SOX2 protein overexpression has previously been noted in high-grade SCLC 31 , and immunoreactive antibodies against SOX2 have been detected in sera from SCLC patients 32 . These observations, together with the frequent amplifications identified here, imply that SOX2 has an important role as a putative lineage-survival oncogene in SCLC. This suggestion is further supported by the correlation of SOX2 expression with SCLC stage and the role of SOX2 expression in maintaining SCLC proliferation.
The recurrent nature of the RLF-MYCL1 fusion and its functional relevance provide additional opportunities for therapeutic intervention in SCLC. Recently, oncogenic kinase gene fusions have become a major focus of interest in the therapeutic targeting of NSCLC [33] [34] [35] . Understanding the role of tumor-specific in-frame kinase fusion transcripts identified in SCLC in this study may provide promising opportunities for targeted therapy development.
URLs. EGA, http://www.ebi.ac.uk/ega/. Table 1) .
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Patient-matched fresh-frozen primary SCLC tumors and normal tissue samples were obtained from commercial sources or the Johns Hopkins tissue repository (Supplementary Table 1) . All samples used in the study had appropriate IRB approval and informed consent from study participants. All tumor and normal tissues were subjected to review by a pathologist to confirm diagnosis and tumor content. The Qiagen AllPrep DNA/RNA kit was used to prepare DNA and RNA.
Exome capture and sequencing. We analyzed the exomes of 42 SCLC samples (30 primary tumor-normal tissue pairs and 12 paired cell lines) and their patient-matched normal samples to assess their mutational burden. We also obtained exome data for an additional 21 SCLC samples that included 5 primary SCLC tumors and 16 SCLC cell lines (Supplementary Table 1) . Exome capture was performed using the Agilent SureSelect Human All Exome kit (38 Mb or 50 Mb). The SureSelect 50 Mb kit includes all of the capture probes from the 38 Mb kit plus some additional content derived from CCDS, GENCODE and RefSeq. Exome capture libraries were sequenced by HiSeq 2000 (Illumina) to generate 2 × 75-bp paired-end data (Supplementary Table 1 ). Targeted mean coverage of 80× and 162× with 96% and 92% of bases covered at ≥10× was achieved for 38 Mb and 50 Mb exome libraries, respectively (Supplementary Table 2 ).
RNA-seq.
We obtained RNA-seq data for 55 samples (24 primary tumornormal tissue pairs, 7 primary tumors, 2 adjacent normal samples and 22 SCLC cell lines) using the TruSeq RNA Sample Preparation kit (Illumina). Libraries were multiplexed two per lane and sequenced on HiSeq 2000 to obtain at least ~30 million paired-end (2 × 75-bp) reads per sample.
Sequence data processing. All sequencing reads were evaluated for quality using the Bioconductor ShortRead package 36 . Sample identity was confirmed by comparing data derived from exome sequencing and RNA-seq against Illumina 2.5 M array data as described 18 .
Variant calling and validation. Sequencing reads were mapped to the UCSC human reference genome (GRCh37/hg19) using Burrows-Wheeler Aligner (BWA) software 37 set to default parameters. Local realignment, duplicate marking and raw variant calling were performed as described previously 38 . Known germline variations represented in dbSNP Build 131 (ref. 39) but not represented in COSMIC v56 (ref. 12) were filtered out. Variations present in the tumor sample but absent in matched normal tissue were predicted to be somatic. Predicted somatic variations were additionally filtered to include only positions with a minimum of 10× coverage in both the tumor and matched normal tissue, as well as an observed variant allele frequency of <3% in the matched normal tissue and a significant difference in variant allele counts, as determined using Fisher's exact test. To control for possible low-level tumor contamination in adjacent normal tissue, the allele frequency cutoff was expanded to 5% if a gene was significantly mutated, allowing for an additional 11 variants to be included. We performed whole-genome sequencing of the 1 hypermutated sample and only report the 755 protein-altering variants that were found in both the exome and whole-genome data for this sample. This sample was excluded from background mutation rate calculations. For unpaired samples, in addition to dbSNP, variants were filtered against normal variants from this data set, as well as normal variants from a published colon data set 18 . In addition, data from 2,500 normal exomes in the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project was used to filter out variants and hotspot mutations. To evaluate the performance of the variant calling algorithm, we randomly selected 594 protein-altering variants and validated them using Sequenom, as described previously 17 . Of these variants, 91% (539) were validated as somatic. All variants that were invalidated were removed from the final set. Variants that were also validated by RNA-seq are labeled as VALIDATED: RNA-Seq to show confirmed expression of the variant (Supplementary Table 3) . Indels were called using the GATK Indel Genotyper Version 2 (ref. 28) . Indel validation was performed as described in a recent study 18 . The effects of all nonsynonymous somatic mutations on gene function were predicted using SIFT 14 , PolyPhen 15 and Condel 16 . All variants were annotated using Ensembl (release 59).
SOX2 knockdown on the amount of SOX2 protein was assessed by protein blot using antibody to SOX2 (Cell Signaling Technology 27485) or GAPDH (Santa Cruz Biotechnology, sc-25778) horseradish peroxidase (HRP)-conjugated secondary antibodies, followed by signal detection with chemiluminescence (GE Healthcare Life Sciences).
Cell viability and proliferation assays. Stable cell lines were plated in quadruplicate at a density of 1 × 10 3 cells per well in opaque 96-well plates in the presence or absence of 2 µg/ml doxycycline. Cells were plated in replicate plates for each time point tested. ATP content was measured as an indicator of metabolically active cells using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) read on a SpectraMax M2e plate reader in luminescence mode (Molecular Devices). Viability was normalized between cell lines at 48 h to correct for differences in the initial number of cells plated in each group. All experiments were repeated a minimum of three times with similar results, and one representative experiment is shown.
Analysis of copy-number variation in SCLC cell lines. SOX2 copy number was assessed by quantitative RT-PCR using TaqMan Copy Number Assays (Hs02719379_cn) on a StepOnePlus Real-Time PCR System (Applied Biosystems). RPPH1 served as the reference gene (Applied Biosystems). Copy-number calls relative to normal human genomic DNA (Promega) were made with CopyCaller v2.0 (Applied Biosystems).
Tissue microarrays. SCLC tissue microarrays were obtained from US Biomax (LC703, LC802a, LC1009 and LC10010a) for IHC and FISH as fresh-cut slides. The four tissue microarrays contain replicate cores and a small set of overlapping cases. For analysis, missing or inconclusive cores were removed, and the replicate or overlapping case core with the highest percentage of tumor area was used for analysis, yielding 110 unique SCLC cases and 15 normal lung cases. Histological diagnosis with SCLC was confirmed by an attending pathologist.
Immunohistochemistry. IHC for SOX2 was performed on the tissue microarrays using a Leica Bond-III automated slide stainer (Leica Microsystems). The 4-µm sections were deparaffinized and subjected to antigen retrieval with Cell Conditioning Solution (high pH CC1 standard, Ventana Medical Systems) for 60 min. Sections were then incubated for 44 min with rabbit monoclonal antibody to SOX2 (1:100 dilution; clone SP76, Cellmarque). Reactions were developed through biotin-free, polymer detection (Ultra-view, Ventana Medical Systems) according to the manufacturer's instructions.
Scoring was performed on each sample. Nuclear labeling was scored by intensity (no (0), weak (1), moderate (2) or strong (3)) and for extent (expressed as the percentage of nuclei that were positive). Results were expressed by assigning a composite IHC score that was calculated by multiplying the intensity score by the percentage of nuclei with positive staining, with a maximum value of 300. FISH analysis. FISH was performed on the tissue microarrays. The BAC clone RP11-459K6 containing a human DNA insert from the genomic region of SOX2 (previously validated by PCR) was used for preparation of the SOX2 FISH probe. The SOX2 probe was validated for chromosome mapping and quality of hybridization in the human lymphoblastoid cell line AG09391 (Coriell Institute).
One slide of each tissue microarray was subjected to a two-color FISH assay using a mixture of the SOX2 probe (red) and a commercially available probe for the chromosome 3 centromere (Kreatech) (green). The steps before hybridization were performed using the Zymed Spot-Light Tissue Pretreatment kit (Invitrogen) according to the manufacturer's instructions.
Analysis was performed on an epifluorescence microscope using single interference filter sets for blue (DAPI), green (FITC) and red (Texas red). For each interference filter, monochromatic images were acquired and merged using CytoVision (Leica Microsystems). Tumor cells were scored for copynumber signals of SOX2 in 30-50 cells. In this analysis, a scoring system was proposed to identify increased levels of copy number per cell. Scores were assigned on a scale from 1-6 (according to pattern of copy-number gain, median per-cell change): 1 (no, 1-2), 2 (low, 2-3), 3 (moderate, 3-4), 4 (high, 4-5), 5 (very high, >5), 6 (gene amplification, gene clusters).
